Regeneron reports preliminary Q4 U.S. sales of Eylea at $1.34 billion

(Reuters) – Regeneron (NASDAQ:) Pharmaceuticals said on Monday its franchise of eye drug Eylea recorded preliminary sales of $1.34 billion in the United States in the fourth quarter. Wells Fargo analyst Mohit Bansal last week pegged consensus Wall Street estimates for U.S. sales of Eylea at $1.53 billion.

The newer higher dose version of the drug generated about $123 million in sales in the quarter in the United States.